Mark M. Moasser, MD

Professor, Department of Medicine (Hematology/Oncology), UCSF

Phone: (415) 353-7070 (appts)
Box 1387, UCSF
San Francisco, CA 94143-1387

View on UCSF Profiles

Additional Websites

• Physician Referral Directory
• Moasser Lab

Education

University of Pennsylvania, Philadelphia, PA, B.A., 1984
Tufts University School of Medicine, Boston, MA, M.D., 1988
The New York Hospital - Cornell Medical Center, New York, NY, 1988-1991, Internal Medicine (Residency)
Memorial Sloan-Kettering Cancer Center, New York, NY, 1991-1996, Medical Oncology (Fellowship)

Professional Experience

• 1996-1999
  Instructor, Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Dept of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
• 1999-2004
  Clinical Assistant, Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Dept Of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
• 2004-2007
  Associate Clinical Professor, Department of Medicine and Cancer Center, Breast Cancer Program, University of California, San Francisco
• 2008-2010
  Associate Professor in Residence, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco
• 2010-present
  Professor in Residence, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco

Honors & Awards

• 1984
  Phi Beta Kappa
• 1992-1993
  Clinical and Molecular Cancer Research Training Fellowship Award
• 1994
  American Society for Clinical Oncology Young Investigator Award (declined)
• 1993-1995
  Charles A. Dana Fellowship Award
• 1993-1995
  Clinical Scholars Award, Biomedical Research Training Program, Sloan-Kettering Institute
• 1995-1996
  Ethel Abbott Fellowship Award
• 1997-1999
  Byrne Fund Award
• 1997-2000
  American Society for Clinical Oncology Career Development Award
• 2002-2006
  American Cancer Society Research Scholar
• 2005-2007
  Susan Komen Breast Cancer Research Foundation Award
• 2005-2006
  California Breast Cancer Research Program Award
• 2008
  Elected to the American Society for Clinical Investigation

Selected Publications

1. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013 Feb 1; 73(3):1168-79.
   View on PubMed
2. Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J. 2012 Nov 1; 447(3):417-25.
   View on PubMed
3. Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM. A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene. 2012 Jan 26; 31(4):419-31.
   View on PubMed
4. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 7; 104(12):1828-35.
   View on PubMed
5. Spassov DS, Ahuja D, Wong CH, Moasser MM. The structural features of Trask that mediate its anti-adhesive functions. PLoS One. 2011; 6(4):e19154.
   View on PubMed
6. Spassov DS, Wong CH, Moasser MM. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell Cycle. 2011 Apr 15; 10(8):1225-32.
   View on PubMed
7. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407.
   View on PubMed
8. Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011 Feb; 31(4):766-82.
   View on PubMed
9. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010 Dec; 21(9):944-50.
   View on PubMed
10. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010 Mar 1; 16(5):1373-83.
    View on PubMed
11. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010 Jan 27; 2(16):16ra7.
    View on PubMed
12. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75.
    View on PubMed
13. Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009 May; 29(5):1071-9.
    View on PubMed
14. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009 May; 174(5):1756-65.
    View on PubMed
15. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009 Apr 1; 15(7):2311-22.
    View on PubMed
16. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7878-83.
    View on PubMed
17. Arkin M, Moasser MM. HER-2-directed, small-molecule antagonists. Curr Opin Investig Drugs. 2008 Dec; 9(12):1264-76.
    View on PubMed
18. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008 Oct 1; 415(1):97-110.
    View on PubMed
19. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008 May; 65(10):1566-84.
    View on PubMed
20. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39.
    View on PubMed

View on UCSF Profiles